Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Aprea Therapeutics IncAPRE-1.660.001.020.37-50.11%-33.52%43.01$3.78-$7.10526$3.7665

Detail of Aprea Therapeutics Inc

 
CEO
Dr. Oren Gilad Ph.D.
Employees
7
Industry
Biotechnology
Sector
Healthcare
Market cap
$22M

Company details

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Aprea Therapeutics Inc
APRE • XNGS • US
$3.7665
-2.17 (-36.17%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.27
Margin profit
0.00%
52 week low
$2.54
52 week high
$8.4899
50-day simple moving average
$3.96
200-day simple moving average
$3.78
Percent held by insiders
11.75%
Percent held by institutions
43.85%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
APRE -40.16%
eps change
APRE 0.00%